BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Uwagawa T, Misawa T, Sakamoto T, Ito R, Gocho T, Shiba H, Wakiyama S, Hirohara S, Sadaoka S, Yanaga K. A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. Ann Oncol. 2009;20:239-243. [PMID: 18836085 DOI: 10.1093/annonc/mdn640] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Hamura R, Haruki K, Fujiwara Y, Tsunematsu M, Shirai Y, Furukawa K, Onda S, Gocho T, Shiba H, Uwagawa T, Usuba T, Fujioka S, Okamoto T, Ikegami T. The effectiveness of adjuvant chemotherapy for Stage I pancreatic cancer based on the UICC 8th edition. Langenbecks Arch Surg 2022. [PMID: 36173461 DOI: 10.1007/s00423-022-02686-3] [Reference Citation Analysis]
2 Uwagawa T, Sakamoto T, Gocho T, Shiba H, Onda S, Yasuda J, Shirai Y, Hamura R, Furukawa K, Yanaga K, Ikegami T. Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer. PLoS ONE 2022;17:e0267623. [DOI: 10.1371/journal.pone.0267623] [Reference Citation Analysis]
3 Choi HW, Naskar M, Seo HK, Lee HW. Tumor-Associated Mast Cells in Urothelial Bladder Cancer: Optimizing Immuno-Oncology. Biomedicines 2021;9:1500. [PMID: 34829729 DOI: 10.3390/biomedicines9111500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Lichterman JN, Reddy SM. Mast Cells: A New Frontier for Cancer Immunotherapy. Cells 2021;10:1270. [PMID: 34063789 DOI: 10.3390/cells10061270] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
5 Uwagawa T, Sakamoto T, Yasuda J, Shiozaki H, Furukawa K, Onda S, Gocho T, Shiba H, Yanaga K. Phase II Study of Adjuvant Chemotherapy With Gemcitabine and Nafamostat Mesilate for Pancreatic Cancer. Pancreas 2021;50:313-6. [PMID: 33835961 DOI: 10.1097/MPA.0000000000001767] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Tharappel AM, Samrat SK, Li Z, Li H. Targeting Crucial Host Factors of SARS-CoV-2. ACS Infect Dis 2020;6:2844-65. [PMID: 33112126 DOI: 10.1021/acsinfecdis.0c00456] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
7 Ghali GZ, Ghali MGZ. Nafamostat mesylate attenuates the pathophysiologic sequelae of neurovascular ischemia. Neural Regen Res 2020;15:2217-34. [PMID: 32594033 DOI: 10.4103/1673-5374.284981] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
8 Chen X, Xu Z, Zeng S, Wang X, Liu W, Qian L, Wei J, Yang X, Shen Q, Gong Z, Yan Y. The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications. Front Oncol 2019;9:852. [PMID: 31552177 DOI: 10.3389/fonc.2019.00852] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
9 Sugano H, Shirai Y, Horiuchi T, Saito N, Shimada Y, Eto K, Uwagawa T, Ohashi T, Yanaga K. Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells. Cancers (Basel) 2018;10:E386. [PMID: 30336548 DOI: 10.3390/cancers10100386] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
10 Murata S, Onozawa S, Yasui D, Ueda T, Sugihara F, Shimizu A, Suzuki K, Satake M. Evaluating the Feasibility of Isolated Pancreatic Perfusion for Chemotherapy Using Computed Tomography: An Experimental Study in Pig Models. Cardiovasc Intervent Radiol 2018;41:1081-8. [PMID: 29582129 DOI: 10.1007/s00270-018-1943-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Shirai Y, Saito N, Uwagawa T, Shiba H, Horiuchi T, Iwase R, Haruki K, Ohashi T, Yanaga K. Pomalidomide promotes chemosensitization of pancreatic cancer by inhibition of NF-κB. Oncotarget 2018;9:15292-301. [PMID: 29632644 DOI: 10.18632/oncotarget.24577] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
12 Dai JJ, Jiang MJ, Wang XP, Tian L. Inflammation-Related Pancreatic Carcinogenesis: Mechanisms and Clinical Potentials in Advances. Pancreas 2017;46:973-85. [PMID: 28796135 DOI: 10.1097/MPA.0000000000000886] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
13 Haruki K, Shiba H, Shimada Y, Shirai Y, Iwase R, Fujiwara Y, Uwagawa T, Ohashi T, Yanaga K. Glycogen synthase kinase-3β activity plays a key role in the antitumor effect of nafamostat mesilate in pancreatic cancer cells. Ann Gastroenterol Surg 2018;2:65-71. [PMID: 29863120 DOI: 10.1002/ags3.12025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
14 Yarla NS, Sukocheva O, Peluso I, Putta S, Bramhachari PV, Yadala R, Tiwari DK, Jagarlamudi S, Scotti L, Scotti MT, Reale M, Kamal MA, Ghulam A, Sharma B, Parvathaneni M, Rao CV, Mannarapu M, Bishayee A. Targeting Arachidonic Acid Pathway-Associated NF-κB in Pancreatic Cancer. Role of Transcription Factors in Gastrointestinal Malignancies 2017. [DOI: 10.1007/978-981-10-6728-0_30] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
15 Fujiwara Y, Shiba H, Uwagawa T, Futagawa Y, Misawa T, Yanaga K. Radical resection of a primarily unresectable pancreatic cancer after neoadjuvant chemotherapy using gemcitabine, ts-1, and nafamostat mesilate; report of a case. Int Surg. 2015;100:287-291. [PMID: 25692432 DOI: 10.9738/INTSURG-D-13-00193.1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
16 Horiuchi T, Uwagawa T, Shirai Y, Saito N, Iwase R, Haruki K, Shiba H, Ohashi T, Yanaga K. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer. J Surg Res 2016;206:1-8. [PMID: 27916347 DOI: 10.1016/j.jss.2016.06.047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
17 Lu YX, Ju HQ, Wang F, Chen LZ, Wu QN, Sheng H, Mo HY, Pan ZZ, Xie D, Kang TB, Chen G, Yun JP, Zeng ZL, Xu RH. Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis. Cancer Lett 2016;380:87-97. [PMID: 27322737 DOI: 10.1016/j.canlet.2016.06.014] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 6.0] [Reference Citation Analysis]
18 Shirai Y, Shiba H, Iwase R, Haruki K, Fujiwara Y, Furukawa K, Uwagawa T, Ohashi T, Yanaga K. Dual inhibition of nuclear factor kappa-B and Mdm2 enhance the antitumor effect of radiation therapy for pancreatic cancer. Cancer Lett 2016;370:177-84. [PMID: 26546875 DOI: 10.1016/j.canlet.2015.10.034] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
19 Leporini C, Ammendola M, Marech I, Sammarco G, Sacco R, Gadaleta CD, Oakley C, Russo E, De Sarro G, Ranieri G. Targeting mast cells in gastric cancer with special reference to bone metastases. World J Gastroenterol 2015; 21(37): 10493-10501 [PMID: 26457010 DOI: 10.3748/wjg.v21.i37.10493] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
20 Marech I, Leporini C, Ammendola M, Porcelli M, Gadaleta CD, Russo E, De Sarro G, Ranieri G. Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment. Cancer Lett 2016;380:216-26. [PMID: 26238184 DOI: 10.1016/j.canlet.2015.07.028] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
21 Murata S, Onozawa S, Mine T, Ueda T, Sugihara F, Yasui D, Kumita S, Shimizu A, Satake M. Minimizing Systemic Leakage of Cisplatin during Percutaneous Isolated Pancreas Perfusion Chemotherapy: A Pilot Study. Radiology 2015;276:102-9. [PMID: 25734552 DOI: 10.1148/radiol.15141596] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Uwagawa T, Yanaga K. Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer. Surg Today 2015;45:1481-8. [PMID: 25673034 DOI: 10.1007/s00595-015-1129-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
23 Ammendola M, Leporini C, Marech I, Gadaleta CD, Scognamillo G, Sacco R, Sammarco G, De Sarro G, Russo E, Ranieri G. Targeting mast cells tryptase in tumor microenvironment: a potential antiangiogenetic strategy. Biomed Res Int. 2014;2014:154702. [PMID: 25295247 DOI: 10.1155/2014/154702] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
24 Ferrand FR, Garcia-Hejl C, Moussaid Y, Schernberg A, Bidard FC, Pavic M, Khenifer S, Stoclin A. [Disseminated intravascular coagulation in solid tumours]. Bull Cancer 2014;101:580-92. [PMID: 24977447 DOI: 10.1684/bdc.2014.1959] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
25 Haruki K, Shiba H, Fujiwara Y, Furukawa K, Iwase R, Uwagawa T, Misawa T, Ohashi T, Yanaga K. Inhibition of nuclear factor-κB enhances the antitumor effect of tumor necrosis factor-α gene therapy for hepatocellular carcinoma in mice. Surgery. 2013;154:468-478. [PMID: 23972653 DOI: 10.1016/j.surg.2013.05.037] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
26 Han S, Lee CW, Trevino JG, Hughes SJ, Sarosi GA Jr. Autocrine extra-pancreatic trypsin 3 secretion promotes cell proliferation and survival in esophageal adenocarcinoma. PLoS One 2013;8:e76667. [PMID: 24146905 DOI: 10.1371/journal.pone.0076667] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
27 Iwase R, Haruki K, Fujiwara Y, Furukawa K, Shiba H, Uwagawa T, Misawa T, Ohashi T, Yanaga K. Combination chemotherapy of nafamostat mesylate with gemcitabine for gallbladder cancer targeting nuclear factor-κB activation. Journal of Surgical Research 2013;184:605-12. [DOI: 10.1016/j.jss.2013.06.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
28 Uwagawa T, Misawa T, Tsutsui N, Ito R, Gocho T, Hirohara S, Sadaoka S, Yanaga K. Phase II study of gemcitabine in combination with regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. Am J Clin Oncol. 2013;36:44-48. [PMID: 22157216 DOI: 10.1097/coc.0b013e31823a53b2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
29 Fujiwara Y, Shiba H, Iwase R, Haruki K, Furukawa K, Uwagawa T, Misawa T, Ohashi T, Yanaga K. Inhibition of Nuclear Factor Kappa-B Enhances the Antitumor Effect of Combination Treatment with Tumor Necrosis Factor-Alpha Gene Therapy and Gemcitabine for Pancreatic Cancer in Mice. Journal of the American College of Surgeons 2013;216:320-332.e3. [DOI: 10.1016/j.jamcollsurg.2012.09.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
30 Gocho T, Uwagawa T, Furukawa K, Haruki K, Fujiwara Y, Iwase R, Misawa T, Ohashi T, Yanaga K. Combination chemotherapy of serine protease inhibitor nafamostat mesilate with oxaliplatin targeting NF-κB activation for pancreatic cancer. Cancer Lett. 2013;333:89-95. [PMID: 23348695 DOI: 10.1016/j.canlet.2013.01.019] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
31 Haruki K, Shiba H, Fujiwara Y, Furukawa K, Iwase R, Uwagawa T, Misawa T, Ohashi T, Yanaga K. Inhibition of nuclear factor-κB enhances the antitumor effect of paclitaxel against gastric cancer with peritoneal dissemination in mice. Dig Dis Sci 2013;58:123-31. [PMID: 22806547 DOI: 10.1007/s10620-012-2311-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
32 Furukawa K, Uwagawa T, Yanaga K. Anti-Tumor Effect of Synthetic Serine Protease Inhibitor. Antitumor Potential and other Emerging Medicinal Properties of Natural Compounds 2013. [DOI: 10.1007/978-94-007-6214-5_13] [Reference Citation Analysis]
33 Kimple RJ, Russo S, Monjazeb A, Blackstock AW. The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer. Expert Rev Anticancer Ther 2012;12:469-80. [PMID: 22500684 DOI: 10.1586/era.12.18] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
34 Furukawa K, Uwagawa T, Haruki K, Fujiwara Y, Iida T, Shiba H, Misawa T, Ohashi T, Yanaga K. Nuclear factor κB activity correlates with the progression and prognosis of pancreatic cancer in a mouse model. Surg Today 2013;43:171-7. [PMID: 22892758 DOI: 10.1007/s00595-012-0279-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
35 Li Q, Wang M, Duan F, Duan L, Ao G, Song P. Pharmacokinetic evaluation of pancreatic arterial infusion chemotherapy with lipid emulsion as a drug carrier in an animal model. Anti-Cancer Drugs 2012;23:713-7. [DOI: 10.1097/cad.0b013e3283512a68] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
36 Tanaka T, Sho M, Nishiofuku H, Sakaguchi H, Inaba Y, Nakajima Y, Kichikaiwa K. Unresectable Pancreatic Cancer: Arterial Embolization to Achieve a Single Blood Supply for Intraarterial Infusion of 5-Fluorouracil and Full-Dose IV Gemcitabine. American Journal of Roentgenology 2012;198:1445-52. [DOI: 10.2214/ajr.11.8008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
37 Hashimoto A, Nishiofuku H, Tanaka T, Sho M, Anai H, Nakajima Y, Kichikawa K. Safety and Optimal Management of Hepatic Arterial Infusion Chemotherapy After Pancreatectomy for Pancreatobiliary Cancer. American Journal of Roentgenology 2012;198:923-30. [DOI: 10.2214/ajr.11.6751] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
38 Fujiwara Y, Furukawa K, Haruki K, Shimada Y, Iida T, Shiba H, Uwagawa T, Ohashi T, Yanaga K. Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor kappa-B inhibition. J Hepatobiliary Pancreat Sci. 2011;18:731-739. [PMID: 21484229 DOI: 10.1007/s00534-011-0390-9] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
39 Furukawa K, Ohashi T, Haruki K, Fujiwara Y, Iida T, Shiba H, Uwagawa T, Kobayashi H, Yanaga K. Combination treatment using adenovirus vector-mediated tumor necrosis factor-alpha gene transfer and a NF-κB inhibitor for pancreatic cancer in mice. Cancer Letters 2011;306:92-8. [DOI: 10.1016/j.canlet.2011.02.036] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
40 Fujiwara Y, Furukawa K, Shimada Y, Iida T, Shiba H, Uwagawa T, Misawa T, Ohashi T, Yanaga K. Combination paclitaxel and inhibitor of nuclear factor κB activation improves therapeutic outcome for model mice with peritoneal dissemination of pancreatic cancer. Pancreas 2011;40:600-7. [PMID: 21343836 DOI: 10.1097/MPA.0b013e31820b9257] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]